Oral Ezatiostat HCl (TLK199) and myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Quddus, Fahd ^a   Clima, Jessica ^b   Seedham, Helen ^b   Sajjad, Ghulam ^b   Galili, Naomi ^b   Raza, Azra ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZATIOSTAT; GLUTATHIONE DERIVATIVE; LENALIDOMIDE; TLK 199; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GAMMA GLU S BZCYS PHGLY DIETHYL ESTER; GAMMA-GLU-S-BZCYS-PHGLY DIETHYL ESTER; GLUTATHIONE; HEMOGLOBIN; THALIDOMIDE;

AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CELL LINEAGE; CHROMOSOME DELETION 5; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 3; CLINICAL FEATURE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; GASTRITIS; HUMAN; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; RELAPSE; CHROMOSOME 2; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME DELETION; DRUG EFFECT; ERYTHROID CELL; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; REMISSION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 5; ERYTHROID CELLS; GLUTATHIONE; HEMOGLOBINS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77951096090     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-16     Document Type: Article

References (7)

1. Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia. N Galili J Cerny A Raza, Curr Treat Options Oncol 2007 8 2 117 28 10.1007/s11864-007-0017-1 17634837
2. How I treat patients with myelodysplastic syndromes. RM Stone, Blood 2009 113 6296 6303 10.1182/blood-2008-09-038935 19383969
3. TLK199: a novel, small molecule myelostimulant. F Meng HE Broxmeyer D Toavs,, et al. Proceedings of the Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24, 2001 Abstract 1144.
4. TLK199 (TelintraTM), a novel glutathione analog inhibitor of GST P1-1, causes proliferation and maturation of bone marrow precursor cells and correlates with clinical improvement in myelodysplastic syndrome (MDS) patients in a phase 2a study. PD Emanuel Z Wang D Cai,, et al. Blood San Diego, CA 2004 652a Abstract 2372.
5. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTp) influences cell proliferation pathways. JE Ruscoe LA Rosario T Wang,, et al. J Pharmacol Exp Ther 2001 298 339 345 11408560
6. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. A Raza N Galili N Callander L Ochoa GL Brown,, et al. J Hematol Oncol 2009 2 20 10.1186/1756-8722-2-20 19439093
7. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. A Raza N Galili S Smith J Godwin GL Brown,, et al. Blood 2009 113 26 6533 40 10.1182/blood-2009-01-176032 19398716